Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diethyltryptamine (DET) is a synthetic psychedelic compound belonging to the tryptamine class, structurally related to DMT (N,N-dimethyltryptamine). Unlike DMT, DET is orally active without the need for monoamine oxidase inhibitors due to its ethyl substitutions, which prevent rapid metabolic degradation. DET acts primarily as an agonist at serotonin 5-HT2A receptor, producing hallucinogenic and psychedelic effects similar to other classic serotonergic psychedelics. Its effects typically last 2–4 hours when taken orally. DET has been studied in clinical settings for its psychoactive properties but has no currently accepted medical use and is classified as a Schedule I controlled substance in the United States[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Diethyltryptamine.